Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries

Author
Husa, Petr
Leblebicioglu, Hakan
Arends, Joop E.
Corti, Giampaolo
Santos, Lurdes
Boesecke, Christoph
Ustianowski, Andrew
Duberg, Ann-Sofi
Ruta, Simona
Salkic, Nermin N.
Lazarevic, Ivana
Pinede, Juan A.
Pshenichnaya, Natalia Yurievna
Tsertswadze, Tengiz
Maticic, Mojca
Puca, Edmond
Abuova, Gulzhan
Gervain, Judit
Bayramli, Ramin
Ahmeti, Salih
Koulentaki, Mairi
Kilani, Badreddine
Vince, Adriana
Negro, Francesco
SÜNBÜL, MUSTAFA
Salmon, Dominique
Ozaras, Resat
Metadata
Show full item record
Abstract
Background. Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in > 95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries.
URI
http://hdl.handle.net/20.500.12627/26837
https://doi.org/10.1016/j.antiviral.2017.12.001
Collections